Pathway Bioventures

Axonis Therapeutics is a biotechnology company focused on developing therapies for neurological disorders by targeting KCC2, a key mediator of inhibition in the brain. The company utilizes a proprietary discovery engine centered on the neuron-specific K-Cl cotransporter (KCC2) to address various conditions, including epilepsy and pain, as well as other central nervous system pathologies. By harnessing breakthrough research from institutions such as Boston Children’s Hospital, Harvard, and Laval University, Axonis aims to enhance the lives of individuals affected by these disorders through improved modulation of neuronal inhibition.

Modifi Biosciences specializes in direct DNA modification and the creation of innovative cancer therapeutics. The company's primary focus is on altering tumor DNA in a way that makes cancer cells irreparable while preserving healthy cells. This distinctive methodology allows researchers to challenge and transform traditional approaches to oncology drug development. By exploiting DNA defects across various cancer types, Modifi Biosciences aims to provide effective treatments that target the underlying genetic issues in tumors, thereby advancing the field of cancer therapeutics.

Afference is an electronics manufacturing company that specializes in wearable technology designed to enhance the interaction between the digital and physical worlds. The company's primary product is a haptic glove that utilizes neural stimulation to simulate the sensation of touch. This innovative device allows users to engage with various digital environments, including extended reality settings and traditional two-dimensional gaming, thereby facilitating a more immersive and realistic experience. Afference aims to enable users to achieve greater digital dexterity with 3D content through its advanced wearable solutions.

IpiNovyx Bio is a biopharmaceutical company focused on creating a novel platform of immunoproteasome-modulating therapeutics aimed at improving the treatment of autoimmune and inflammatory diseases. The company's innovative approach involves developing inhibitors that selectively target the immunoproteasome, which plays a critical role in regulating specific immune cell types. By modulating these immune responses, IpiNovyx Bio seeks to enable patients to recover more effectively from their conditions and enhance their overall health.

miRecule, Inc. is a biotechnology company based in Gaithersburg, Maryland, established in 2016. The company specializes in developing a microRNA-based drug discovery platform, DREAmiR, aimed at addressing challenges in cancer therapy and muscular dystrophy. This innovative platform leverages genomic and outcome data from thousands of patients to identify genetic abnormalities associated with diseases. miRecule formulates RNA therapeutics that can directly target and correct these genetic issues. The platform integrates genomic sequencing, expression, and prognostic data from numerous cancer patients with high throughput screening of microRNA candidates for replacement therapy. miRecule is focused on creating highly tailored therapeutics, with lead programs targeting Head & Neck Cancer and Facioscapulohumeral Muscular Dystrophy, ultimately striving to improve the quality of life for patients suffering from debilitating conditions.

CytoVale, Inc. is a medical technology company based in San Francisco, California, established in 2012. The company specializes in developing biomarkers that leverage the mechanical properties of individual cells, a field known as mechanomics. By utilizing microfluidics technology, CytoVale can efficiently route and physically probe single cells to measure multiple biomarkers simultaneously. This innovative approach aims to enhance early detection of immune-mediated diseases, particularly sepsis, thereby improving patient outcomes and reducing treatment costs. CytoVale's integration of cell mechanics with machine learning positions it at the forefront of revolutionizing diagnostic practices in healthcare.

Dimension Inx Corp. focuses on designing and developing three-dimensional (3D) printable materials and painted objects for research and commercial applications. The company specializes in creating regenerative microenvironments that aid the body in self-healing. Its biomaterials platform incorporates a complex interplay of material composition, microstructure, and microarchitecture to enhance biofunctionality. Dimension Inx offers a range of products, including Hyperelastic Bone for bone regeneration, 3D printable elastomers, bioactive ceramics, and solutions for soft tissue regeneration. Founded in 2016 and based in Chicago, Illinois, the company aims to provide innovative therapeutic products that restore tissue and organ function, potentially reducing the need for organ transplantation through advanced bio-fabrication processes.

miRecule, Inc. is a biotechnology company based in Gaithersburg, Maryland, established in 2016. The company specializes in developing a microRNA-based drug discovery platform, DREAmiR, aimed at addressing challenges in cancer therapy and muscular dystrophy. This innovative platform leverages genomic and outcome data from thousands of patients to identify genetic abnormalities associated with diseases. miRecule formulates RNA therapeutics that can directly target and correct these genetic issues. The platform integrates genomic sequencing, expression, and prognostic data from numerous cancer patients with high throughput screening of microRNA candidates for replacement therapy. miRecule is focused on creating highly tailored therapeutics, with lead programs targeting Head & Neck Cancer and Facioscapulohumeral Muscular Dystrophy, ultimately striving to improve the quality of life for patients suffering from debilitating conditions.

Simergent, LLC is a company that manufactures automated peritoneal dialysis devices aimed at providing affordable home dialysis solutions for both developed and emerging markets. Founded in 2014, the company is headquartered in Oklahoma City, Oklahoma, with additional operations in Chicago, Illinois. Simergent's devices are designed to be cost-effective and user-friendly, featuring a disposable tubing set that operates independently to troubleshoot issues. This innovation allows patients to maintain a normal lifestyle and socialize with family and friends while undergoing treatment at home.

Scioto Biosciences, Inc. is a clinical-stage biotechnology company based in Indianapolis, Indiana, founded in 2017. The company develops an Activated Bacterial Therapeutics (ABT) platform designed to deliver live bacteria to the gut, focusing on enhancing the efficacy of microbiome therapeutics. This innovative platform allows for the sustained presence of active therapeutic bacteria in the gastrointestinal tract, promoting adhesion to the intestinal mucosa. Scioto Biosciences aims to create transformative therapies that can improve healing for various conditions, particularly those related to the central nervous system and gastrointestinal disorders. The company's research emphasizes optimizing therapeutic functions, increasing gut survival, and facilitating mucosal thickening, which may lead to better treatment outcomes in severe gut injury models.